Skip to main content

Month: April 2022

Proactive news headlines including Cooper Metals, Oar Resources, Magnis Energy Technologies and International Graphite

Sydney, April 26, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: Cooper Metals Ltd (ASX:CPM) has secured a contract for 20 holes and 2,000 metres of reverse circulation drilling at King Solomon and Python prospects of the Mt Isa East Copper-Gold Project in northwest Queensland, part of an expansive exploration effort which will include a large airborne versatile domain electromagnetic (VTEM) survey. Click here Oar Resources Ltd (ASX:OAR) has identified an opportunity to put its Oakdale Graphite Project back on the map following a detailed assessment of the Eyre Peninsula, South Australia based project. Click here Magnis Energy Technologies Ltd (ASX:MNS, OTCQX:MNSEF) subsidiary Imperium3 New York (iM3NY) continues to...

Continue reading

Tryg A/S – Q1 report 2022

Tryg’s Supervisory Board has today approved the interim report for Q1 2022.Tryg stand-alone reported a premium growth of 5.1% (6.2% in Q1 2021) primarily driven by the Private and Commercial segments, a highest ever Q1 technical result of DKK 754m (DKK 751m) which was positively impacted by a positive top-line growth, improved underlying business, but partly offset by higher large and weather claims compared to the prior-year period. The new Swedish business, Trygg-Hansa, whose results are booked under the investment income for the last time, has reported a premiums growth of approximately 3% and a highly satisfactory technical result of DKK 621m, driven by a combined ratio of 73.3, and a slightly improving underlying performance. The investment result of DKK -284m included Tryg stand-alone investment result (DKK -124m) and the income...

Continue reading

Press release Orange : Q1 2022 results – Revenue growth and improved EBITDAaL margin

Press releaseParis, 26 April 2022 Financial information at 31 March 2022 Revenue growth and improved EBITDAaL margin Retail services reap full benefits of value strategy and improved customer experience In millions of euros   1Q 2022 1Q 2021comparablebasis 1Q 2021historicalbasis changecomparablebasis changehistoricalbasis Revenues   10,582 10,511 10,315 0.7 % 2.6 % EBITDAaL   2,620 2,595 2,565 1.0 % 2.2 % eCAPEX (excluding licenses)   1,610 1,708 1,760 (5.8)% (8.6)% EBITDAaL – eCAPEX   1,011 887 805 13.9 % 25.6 % Revenues rose 0.7%1 in the first quarter, driven by Africa & Middle East (+8.7%). Growth in retail services was well above the decline in Wholesale services. In France, the faster pace of retail services growth has yet to offset the decline in Wholesale. Revenues fell slightly, by 0.7%. Revenues in...

Continue reading

Valneva Announces Upsized Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed

Up to an additional $40 million made available as part of the agreement Saint–Herblain (France), April 26, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement to increase the principal amount of its existing $60 million debt financing agreement with funds managed by leading US-based healthcare investment firms Deerfield Management Company and OrbiMed. This extension will provide Valneva immediate access to $20 million, with an additional $20 million available upon potential conditional approval of its inactivated COVID-19 vaccine candidate, VLA2001, by the European Medicines Agency. The increased funding will be used to further invest in R&D, including market access preparations for Valneva’s chikungunya vaccine candidate, VLA1553. Peter Bühler, Chief Financial Officer...

Continue reading

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

Strong immunogenicity profile observed in study participants aged 5-17 years one month after the primary vaccination series Safety profile observed in pediatric participants similar to previously reported data in adult participants Pediatric population to be included in planned Phase 3 trial – expected to start in Q3 2022, subject to regulatory approval Saint-Herblain (France) and New York, April 26, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. Based on these new results, Valneva and Pfizer plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial. The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected...

Continue reading

eQ Plc’s interim report Q1 2022 – eQ’s year started off excellently

eQ Plc interim report26 April 2022 at 8:00 AM January to March 2022 in brief The Group’s net revenue during the period was EUR 21.7 million (EUR 18.0 million from 1 Jan. to 31 March 2021). The Group’s net fee and commission income was EUR 21.4 million (EUR 15.8 million). The Group’s net investment income from own investment operations was EUR 0.3 million (EUR 2.2 million), including the return from private equity and real estate fund investments and liquid fixed income funds. The Group’s operating profit grew by 23% to EUR 13.0 million (EUR 10.6 million). The Group’s profit was EUR 10.3 million (EUR 8.4 million). The consolidated earnings per share were EUR 0.26 (EUR 0.22). The net revenue of the Asset Management segment increased by 32% to EUR 19.6 million (EUR 14.8 million) and the operating profit by 43% to EUR 12.6 million...

Continue reading

Aspocomp’s Interim Report January 1-March 31, 2022: Net sales increased by 45 percent and operating result improved significantly in the first quarter

Aspocomp Group Plc, Interim Report, April 26, 2022 at 8:00 a.m. EEST FIRST QUARTER 2022 HIGHLIGHTS Net sales EUR 9.0 (6.2) million, increase of 45% Operating result EUR 0.8 (-0.5) million, 8.9% (-8.0%) of net sales Earnings per share EUR 0.11 (-0.07) Operative cash flow EUR 0.7 (-0.1) million Equity ratio 66.9% (62.7%), increase of 4% Order book at the end of the review period EUR 20.5 (5.3) million, increase of 284% Orders received EUR 13.0 (8.0) million, increase of 63% OUTLOOK FOR 2022 Demand is expected to improve in all customer segments. However, a global shortage of components may limit growth in customer demand. The company’s full-year guidance remains unchanged. Aspocomp estimates that its net sales for 2022 will increase and its operating result for 2022 will improve from 2021. In 2021, net sales amounted to EUR 33.2...

Continue reading

Forvia Sales Q1 2022

                                                                Nanterre (France), April 26, 2022 FIRST-QUARTER 2022 SALES Q1 2022 SALES OF €5.3bn, UP 33% ON A REPORTED BASIS (including first two months of consolidation of HELLA) ORGANIC SALES GROWTH OF +1.1% (Faurecia stand-alone), OUTPERFORMING AUTOMOTIVE PRODUCTION BY 530bps FIRST RELEASE OF FORVIA’S FY 2022 GUIDANCE (including 11 months of consolidation of HELLA) INCREASED FINANCIAL FLEXIBILITY TO GET THROUGH THE CURRENT UNCERTAIN ENVIRONMENT, thanks to covenant renegotiation, suspended dividend payment in 2022 and upgraded asset divestment program by end 2023 in €m Q1 2021 Currency effect Organic            growth Scope effect   (HELLA 2 months) Q1 2022 Reported change Group sales 4,005 129 46 1,143 5,322 +32.9% % last year’s sales   +3.2% ...

Continue reading

Aker Horizons and Statkraft Partnering to Explore Green Hydrogen and Ammonia Opportunities in India and Brazil

Aker Horizons, through its portfolio company Aker Clean Hydrogen, and Statkraft have signed collaboration agreements to jointly explore opportunities for green hydrogen and ammonia production in India and Brazil, targeting local steel and fertilizer industries. The collaboration brings together Aker Clean Hydrogen, a global integrated hydrogen, ammonia and methanol producer building on Aker’s 180 years of industrial heritage, and Statkraft, a leading developer and generator of renewable energy with a substantial experience and presence in India and Brazil. “With considerable renewable energy production and market activities in India and Brazil, Statkraft is well positioned to capture green hydrogen opportunities in these two huge and important energy markets. Developing such opportunities helps us grow our business and reduces greenhouse...

Continue reading

SMCP – 2022 Q1 Sales

2022 First QuarterPress release – Paris, April 26th, 2022 Q1 Sales up +24% driven by LFL, thanks to strong local demandAmericas and EMEA outstanding momentumContinuation of full price strategyDigital penetration of 25% Q1 Sales at €283.0m, up +23.7% on an organic1 basis vs. 2021, fully driven by a LFL2 growth thanks to strong local demand Outstanding momentum in the Americas and EMEA3 (resp.+44.5% and +72.9% on an organic basis vs. 2021) Despite a good start to the quarter in APAC4 (successful Chinese New Year), recent Covid restrictions had a significant impact on sales, first in Hong-Kong and later in Mainland China Progressive improvement in France over the quarter, outperforming the market Successful execution of the One journey strategic plan, including: Continuation of the full price strategy (discount rate down by -6.1 pp...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.